Clinical effects of butorphanol combined with dexmedetomidine versus propofol in fiberoptic bronchoscopy

Objective To observe the clinical effect of butorphanol combined with dexmedetomidine or propofol in fiberoptic bronchoscopy. Methods Fifty patients undergoing fiberoptic bronchoscopy in our hospital from February to August, 2019 were randomly divided into group A and group B, 25 cases for each group. All the patients were subjected to topical anesthesia with lidocaine aerosol. In group A, dexmedetomidine was infused intravenously at 0.5 μg/kg for 15 minutes, maintained at 0.5 μg/(kg·h); and butorphanol was infused intravenously at 0.02 mg/kg 5 minutes before examination. In group B, 0.02 mg/kg butorphanol was injected intravenously 5 minutes before the examination, and plasma target-controlled propofol was given 3 μg/ml. The hemodynamic parameters, such as MAP, HR, and SPO2, as well as anesthesia effect and adverse reactions were recorded at the times of entry (T1), arrival of glottis (T2), passage of tracheal carina (T3), diagnosis and treatment (T4), and withdrawal from fiberoptic bronchoscopy (T5). Results At T2, T3, and T4, the mean blood pressures and the heart rates were lower in group A than in group B [(81±10) mmHg vs. (101±12) mmHg, (86±12) mmHg vs. (98±9) mmHg, (85 ±9) mmHg vs. (92±13) mmHg, (68±8) times/min vs. (98±12) times/min, (72±8) times/min vs. (88±11) times/min, and (70±9) times/min vs. (85±12) times/min; all P 0.05). No nausea or vomiting occurred in both groups. Conclusion The application of butorphanol and dexmedetomidine in fiberoptic bronchoscopy is safe and feasible, with good anesthetic effect and few adverse reactions. Key words: Dexmedetomidine; Butorphanol; Target control; Propofol; Fiberoptic bronchoscopy